Clinical recommendations derived from an ADVI Health-led expert panel are now part of the 2024 American Diabetes Association (ADA) “Standards of Care.” In 2022, ADVI Health’s chief economist, strategic analytics, value and economics, Michael Broder, MD, guided a group of oncologists and endocrinologists in the development of expert recommendations for managing hyperglycemia associated with the use of alpelisib (a selective PI3K inhibitor).

This panel’s expert guidance has now been included in the Nature Journal, NPJ Breast Cancer, titled, “Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.”

Read the full study in Nature.